VivoSeq
Oncology

Advanced Non-Small Cell Lung Cancer

9

Pipeline Programs↗

5

Active Trials↗

9

Companies Involved↗

Advanced Non-Small Cell Lung Cancer is an early-stage landscape with 9 programs across 9 companies. The most active players are Pfizer, Merck & Co., Syndax Pharmaceuticals. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3S

Syndax Pharmaceuticals

1 program

Phase 3Bayer logo

Bayer

4 programs

PreclinicalRegeneron logo

Regeneron

2 programs

PreclinicalEli Lilly logo

Eli Lilly

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody343%

Modality classified for 67% of 12 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Available1 · 17%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Recruiting·MMirati Therapeutics Inc.·Preclinical·NCT04613596·626 enrolled
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Recruiting·Pfizer logoPfizer·Phase 3·NCT07222566·1,410 enrolled
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
Recruiting·Bayer logoBayer·Preclinical·NCT05099172·400 enrolled
A Real-World Evaluation of Tislelizumab Treatment Patterns and Effectiveness in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Recruiting·BBeOne Medicines·N/A·NCT07652736·440 enrolled
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
Active, not recruiting·Regeneron logoRegeneron·Preclinical·NCT05785767·149 enrolled
An Expanded Access Program to Provide Oral Sevabertinib (BAY 2927088) in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring an HER2 (Human Epidermal Growth Factor Receptor 2) Activating Mutation
Available·Bayer logoBayer·N/A·NCT06761976

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)